Personal tools

MCL coexpression mm9:669: Difference between revisions

From FANTOM5_SSTAR

Jump to: navigation, search
No edit summary
No edit summary
Line 6: Line 6:
|ontology_enrichment_disease=
|ontology_enrichment_disease=
|ontology_enrichment_uberon=UBERON:0004177!3.74e-10!29;UBERON:0005057!3.74e-10!29;UBERON:0000077!1.57e-09!35;UBERON:0000926!4.33e-09!120;UBERON:0004120!4.33e-09!120;UBERON:0006603!4.33e-09!120;UBERON:0002193!4.47e-09!48;UBERON:0002405!4.47e-09!48;UBERON:0002390!8.71e-09!45;UBERON:0003061!8.71e-09!45;UBERON:0006562!1.86e-08!24;UBERON:0001557!1.86e-08!24;UBERON:0001042!1.86e-08!24;UBERON:0008814!1.86e-08!24;UBERON:0009145!1.86e-08!24;UBERON:0002370!2.03e-08!23;UBERON:0000974!2.03e-08!23;UBERON:0004807!2.03e-08!23;UBERON:0005058!2.03e-08!23;UBERON:0003351!2.03e-08!23;UBERON:0009113!2.03e-08!23;UBERON:0003295!2.03e-08!23;UBERON:0009722!2.03e-08!23;UBERON:0005562!2.03e-08!23;UBERON:0007690!2.03e-08!23;UBERON:0000153!2.09e-08!43;UBERON:0000072!9.17e-08!27;UBERON:0003408!1.04e-07!24;UBERON:0007811!1.18e-07!36;UBERON:0003081!5.82e-07!87;UBERON:0000065!8.73e-07!41
|ontology_enrichment_uberon=UBERON:0004177!3.74e-10!29;UBERON:0005057!3.74e-10!29;UBERON:0000077!1.57e-09!35;UBERON:0000926!4.33e-09!120;UBERON:0004120!4.33e-09!120;UBERON:0006603!4.33e-09!120;UBERON:0002193!4.47e-09!48;UBERON:0002405!4.47e-09!48;UBERON:0002390!8.71e-09!45;UBERON:0003061!8.71e-09!45;UBERON:0006562!1.86e-08!24;UBERON:0001557!1.86e-08!24;UBERON:0001042!1.86e-08!24;UBERON:0008814!1.86e-08!24;UBERON:0009145!1.86e-08!24;UBERON:0002370!2.03e-08!23;UBERON:0000974!2.03e-08!23;UBERON:0004807!2.03e-08!23;UBERON:0005058!2.03e-08!23;UBERON:0003351!2.03e-08!23;UBERON:0009113!2.03e-08!23;UBERON:0003295!2.03e-08!23;UBERON:0009722!2.03e-08!23;UBERON:0005562!2.03e-08!23;UBERON:0007690!2.03e-08!23;UBERON:0000153!2.09e-08!43;UBERON:0000072!9.17e-08!27;UBERON:0003408!1.04e-07!24;UBERON:0007811!1.18e-07!36;UBERON:0003081!5.82e-07!87;UBERON:0000065!8.73e-07!41
|tfbs_overrepresentation_for_novel_motifs=0.795069,0.286791,0.7433,0.878892,0.176699,0.342839,0.425757,0.345089,0.362206,1.77702,1.00157,0.414631,0.345518,1.95087,0.189961,0,0.619876,0.170475,0.656134,0.171249,0.238546,0.0281659,1.11256,0.520732,0.276437,1.16974,0.0908349,0.949712,1.79888,0.231659,0.349031,0.717576,0.504188,0.570676,0.556756,0.075793,2.15646,0.411296,0.144953,0.782839,0.51597,0.353696,0.0243896,0.191571,1.45562,0.856658,0.543674,0.376103,0.208261,0.61724,0.603113,1.22385,0.479906,0.855661,0.87275,1.12875,0.223087,1.03993,0.288386,1.12465,0.698157,1.24284,0.120887,0.592318,1.15114,0.631188,1.00675,1.3527,0.693631,1.20659,0.706068,0.355763,0.871379,0.905636,2.01635,1.39651,0.570456,0.532872,0.681539,0.242107,0.110993,1.53784,0.495545,0.101814,1.86182,0.981923,0.143445,0.500771,2.31991,1.51408,1.07554,0.797601,0.730003,0.181374,0.437593,0.129056,0.104462,0.732731,0.543917,0.437273,0.943642,0.717305,0.838603,0.603683,0.602672,0.930972,0.660145,0.372438,1.97481,1.25266,0.781068,3.24951,0.681364,1.01194,1.0825,0.172131,0.566805,0.886406,0.621127,0.158673,0.910937,0.572279,0.464505,0.532013,1.13603,0.685116,0.433317,1.7186,1.00525,0.183744,0.821997,0.323373,0.976125,0.456508,1.10385,0.115066,0.300001,0.934673,1.05527,1.88134,1.48237,1.01139,0.475785,0.727736,0.596462,0.354106,0.546641,1.84176,0.816464,1.60254,0.235808,1.9884,0.857198,0.415832,0.455644,0.93735,0.488969,0.57908,0.290467,0.811219,1.06466,0.791909,0.685546,1.41739,0.593295,0.448733,0.939822,0.413167,0.451293
}}
}}

Revision as of 18:43, 26 November 2012


Phase1 CAGE Peaks

 Short description
Mm9::chr13:49748436..49748466,+p2@Nol8
Mm9::chr13:49748467..49748505,+p3@Nol8
Mm9::chr15:34012419..34012489,+p1@Mtdh
Mm9::chr15:81958346..81958431,+p1@Ccdc134
Mm9::chr1:43990825..43990921,+p1@Tpp2
Mm9::chr4:48486254..48486273,-p2@Tex10
Mm9::chr5:21290933..21291050,-p1@Dnajc2
Mm9::chr6:71582645..71582688,-p2@Kdm3a
Mm9::chr8:127421777..127421801,+p1@Gm505
Mm9::chr8:32279219..32279241,-p2@Mak16
Mm9::chr9:14588950..14589021,-p1@Ankrd49


Enriched pathways on this co-expression cluster<b>Summary:</b><br>Canonical pathway gene sets were compiled from Reactome, Wikipathways and KEGG. For the major signaling pathways, the transcriptionally-regulated genes (downstream targets) were obtained from Netpath. Combined, the canonical pathways and downstream targets totaled 489 human gene sets. The corresponding M. musculus gene sets were inferred by homology using the HomoloGene database. Enrichment for each of the canonical 489 pathways and gene sets included in the co-expression cluster was assessed by the hypergeometric probability. The resulting P values were also then adjusted by the Benjamini-Hochberg method for multiple comparisons.<br><b>Analyst: </b>Emmanuel Dimont<br><br>link to source dataset<br>data


GO IDGO nameFDR corrected p-value
GO:0004294tripeptidyl-peptidase II activity0.0101342096230186
GO:0000085G2 phase of mitotic cell cycle0.0101342096230186
GO:0008240tripeptidyl-peptidase activity0.0101342096230186
GO:0051319G2 phase0.0101342096230186
GO:0003676nucleic acid binding0.0319481498724259
GO:0004289subtilase activity0.047230829021569



Relative expression of the co-expression cluster over median <br>Analyst:





Enriched sample ontology terms on this co-expression cluster<b>Summary:</b>To summarize promoter activities (expression profile of a TSS region) across ~1000 samples, we performed enrichment analysis based on FANTOM5 Sample Ontology (FF ontology). The question here is “in which type of samples the promoter is more active”. To answer this question, we compared expressions (TPMs) in the samples associated with a sample ontology term and the rest of the samples by using the Mann-Whitney rank sum test. To summarize ontologies enriched in this co-expression cluster, we ran the same analysis on an averaged expression profile of all promoters that make up. <b>Analyst:</b> Hideya Kawaji <br><br>links to source dataset<br><br>cell_data<br>uberon_data<br><br>


Uber Anatomy
Ontology termp-valuen
hemopoietic organ3.74e-1029
immune organ3.74e-1029
mixed endoderm/mesoderm-derived structure1.57e-0935
mesoderm4.33e-09120
mesoderm-derived structure4.33e-09120
presumptive mesoderm4.33e-09120
hemolymphoid system4.47e-0948
immune system4.47e-0948
hematopoietic system8.71e-0945
blood island8.71e-0945
pharynx1.86e-0824
upper respiratory tract1.86e-0824
chordate pharynx1.86e-0824
pharyngeal arch system1.86e-0824
pharyngeal region of foregut1.86e-0824
thymus2.03e-0823
neck2.03e-0823
respiratory system epithelium2.03e-0823
hemolymphoid system gland2.03e-0823
pharyngeal epithelium2.03e-0823
thymic region2.03e-0823
pharyngeal gland2.03e-0823
entire pharyngeal arch endoderm2.03e-0823
thymus primordium2.03e-0823
early pharyngeal endoderm2.03e-0823
anterior region of body2.09e-0843
segment of respiratory tract9.17e-0827
gland of gut1.04e-0724
craniocervical region1.18e-0736
lateral plate mesoderm5.82e-0787
respiratory tract8.73e-0741


TFBS overrepresentation<b>Summary:</b>The values shown are the p-values for overrepresentation of the motif in this coexpression cluster. So a small p-value means a strong overrepresentation. <b>Analyst:</b> Michiel de Hoon <br><br>link to source data <br> Novel motifs <br>data <br><br> Jaspar motifs <br>data


Novel motifs




JASPAR motifs


Motifs-log10(p-value)

{{{tfbs_overrepresentation_jaspar}}}